These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38156444)

  • 1. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
    Kim JL; Gerrie AS; Savage KJ; Villa D; Scott D; Craig JW; Farinha P; Skinnider B; Slack G; Connors JM; Sehn LH; Venner C; Freeman CL
    Leuk Lymphoma; 2024 Mar; 65(3):346-352. PubMed ID: 38156444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
    Olszewski AJ; Butera JN; Reagan JL; Castillo JJ
    Am J Hematol; 2020 Apr; 95(4):354-361. PubMed ID: 31849108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
    Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
    Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
    Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
    Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
    Kapoor P; Paludo J; Abeykoon JP
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):671-687. PubMed ID: 37246086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing.
    Arulogun SO; Brian D; Goradia H; Cooney A; Menne T; Koo R; O'Neill AT; Vos JMI; Pratt G; Turner D; Marshall K; Manos K; Anderson C; Gavriatopoulou M; Kyriakou C; Kersten MJ; Minnema MC; Koutoumanou E; El-Sharkawi D; Linton K; Talaulikar D; McCarthy H; Bishton M; Follows G; Wechalekar A; D'Sa SP
    Am J Hematol; 2023 May; 98(5):750-759. PubMed ID: 36866925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
    Olszewski AJ; Reagan JL; Castillo JJ
    Am J Hematol; 2018 Jan; 93(1):E1-E3. PubMed ID: 28960532
    [No Abstract]   [Full Text] [Related]  

  • 8. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.
    Tedeschi A; Picardi P; Ferrero S; Benevolo G; Margiotta Casaluci G; Varettoni M; Baratè C; Motta M; Gini G; Goldaniga MC; Visco C; Zaja F; Belsito Petrizi V; Ravelli E; Gentile M; Urbano MA; Franceschetti S; Ghione P; Orsucci L; Frustaci AM; Gaidano G; Vitolo U; Morra E
    Leuk Lymphoma; 2015; 56(9):2637-42. PubMed ID: 25651423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
    Flinn IW; van der Jagt R; Kahl BS; Wood P; Hawkins TE; Macdonald D; Hertzberg M; Kwan YL; Simpson D; Craig M; Kolibaba K; Issa S; Clementi R; Hallman DM; Munteanu M; Chen L; Burke JM
    Blood; 2014 May; 123(19):2944-52. PubMed ID: 24591201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.
    Ioakimidis L; Patterson CJ; Hunter ZR; Soumerai JD; Manning RJ; Turnbull B; Sheehy P; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):62-6. PubMed ID: 19362976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
    Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
    J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
    Chien HC; Morreall D; Patil V; Rasmussen KM; Yong CM; Li CY; Passey DG; Burningham Z; Sauer BC; Halwani AS
    Am J Hematol; 2021 Jun; 96(6):E184-E187. PubMed ID: 33606890
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
    Laribi K; Poulain S; Willems L; Merabet F; Herbaux C; Roos-Weil D; Laribi de Materre I; Roussel X; Nudel M; Tricot S; Dupuis J; Le Calloch R; Bareau B; Leblond V
    Br J Haematol; 2024 Jun; 204(6):2233-2236. PubMed ID: 38504454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
    Buske C
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario.
    Suleman A; Aktar SJ; Ante Z; Liu N; Chan KKW; Cheung MC; Prica A
    Br J Haematol; 2023 Sep; 202(6):1104-1118. PubMed ID: 37474340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: A retrospective analysis of an administrative claims database.
    Dote S; Inose R; Goto R; Kobayashi Y; Muraki Y
    Hematol Oncol; 2023 Aug; 41(3):354-362. PubMed ID: 36792059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.